Angiomax Rtu is a drug owned by Maia Pharmaceuticals Inc. It is protected by 3 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 20, 2039. Details of Angiomax Rtu's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11903993 | Ready-to-use bivalirudin compositions |
May, 2039
(14 years from now) | Active |
| US11918622 | Ready-to-use bivalirudin compositions |
May, 2039
(14 years from now) | Active |
| US11992514 | Ready-to-use bivalirudin compositions |
May, 2039
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Angiomax Rtu's patents.
Latest Legal Activities on Angiomax Rtu's Patents
Given below is the list of recent legal activities going on the following patents of Angiomax Rtu.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Sequence Moved to Public Database | 15 Mar, 2024 | US11918622 |
| Patent eGrant Notification | 05 Mar, 2024 | US11918622 |
| Recordation of Patent eGrant | 05 Mar, 2024 | US11918622 |
| Patent Issue Date Used in PTA Calculation Critical | 05 Mar, 2024 | US11918622 |
| Recordation of Patent Grant Mailed Critical | 05 Mar, 2024 | US11918622 |
| Email Notification Critical | 05 Mar, 2024 | US11918622 |
| Mail Patent eGrant Notification | 05 Mar, 2024 | US11918622 |
| Sequence Moved to Public Database | 29 Feb, 2024 | US11903993 |
| Patent eGrant Notification | 20 Feb, 2024 | US11903993 |
| Mail Patent eGrant Notification | 20 Feb, 2024 | US11903993 |
US patents provide insights into the exclusivity only within the United States, but Angiomax Rtu is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Angiomax Rtu's family patents as well as insights into ongoing legal events on those patents.
Angiomax Rtu's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Angiomax Rtu's generic launch date based on the expiry of its last outstanding patent is estimated to be May 20, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Angiomax Rtu Generic API suppliers:
Bivalirudin is the generic name for the brand Angiomax Rtu. 10 different companies have already filed for the generic of Angiomax Rtu, with Hospira having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Angiomax Rtu's generic
Alternative Brands for Angiomax Rtu
Angiomax Rtu which is used for preventing blood clots in patients undergoing percutaneous coronary intervention (PCI)., has several other brand drugs using the same active ingredient (Bivalirudin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Sandoz |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Bivalirudin, Angiomax Rtu's active ingredient. Check the complete list of approved generic manufacturers for Angiomax Rtu
About Angiomax Rtu
Angiomax Rtu is a drug owned by Maia Pharmaceuticals Inc. It is used for preventing blood clots in patients undergoing percutaneous coronary intervention (PCI). Angiomax Rtu uses Bivalirudin as an active ingredient. Angiomax Rtu was launched by Maia Pharms Inc in 2019.
Approval Date:
Angiomax Rtu was approved by FDA for market use on 25 July, 2019.
Active Ingredient:
Angiomax Rtu uses Bivalirudin as the active ingredient. Check out other Drugs and Companies using Bivalirudin ingredient
Treatment:
Angiomax Rtu is used for preventing blood clots in patients undergoing percutaneous coronary intervention (PCI).
Dosage:
Angiomax Rtu is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 250MG/50ML (5MG/ML) | SOLUTION | Prescription | INTRAVENOUS |